Medytox announced on Oct. 24 that it has withdrawn its application to China’s National Medical Products Administration (NMPA), which was filed in 2018 for the import of its Meditoxin product (export name: Neuronox). Instead, the company will actively push for its entry into the Chinese market with its next-generation toxin product Newlux, developed by its affiliate NUMECO.
The decision is based on the assessment that, considering the future growth potential of the Chinese market, entering with the large-scale production-ready Newlux—which employs the latest manufacturing processes—is strategically more advantageous than the previous plan.
Medytox has already commenced large-scale production of Newlux at its Osong Plant 3, which has a production capacity several times larger than that of Ochang Plant 1. The company has also initiated discussions with several overseas pharmaceutical companies for a swift entry into the Chinese market.
It was concluded that although Meditoxin, supplied to various countries overseas, is solely produced at Ochang Plant 1, there could be obstacles in ensuring a smooth supply even if approval is obtained from China in the future.
A Medytox official stated, “The decision to introduce Newlux to China is a strategic move by Medytox to successfully capture the global toxin market. It is a proactive measure to establish a more stable global supply chain in response to market demand.”